[Combined cefotaxime and amikacin for immunomodulation in the treatment of actinomycetoma resistant to conventional treatment]

Gac Med Mex. 1999 Sep-Oct;135(5):517-21.
[Article in Spanish]

Abstract

Actinomycetoma is a chronic disease that affects subcutaneous tissue. We present a case of a patient with abdominal actinomycetoma caused by Nocardia brasiliensis resistant to different treatments over several years, who also presented phagocyte immunodeficiency. He received two cycles (23 day cycles) of cefotaxime, 1 g every 8-h, and amikacin, 500 mg every 12 hours. Immunomodulation was carried out with levamisole 300 mg per week, during 4 weeks and bacterial antigen (at a concentration of 600,000,000 bacteria per mL), twice for a week during 20 months. The importance of susceptibility testing and immunological function investigation in this type of patients is discussed.

Publication types

  • Case Reports
  • English Abstract
  • Review

MeSH terms

  • Abdominal Muscles
  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • Amikacin / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Cefotaxime / therapeutic use*
  • Cephalosporins / therapeutic use*
  • Chronic Disease
  • Drug Resistance, Microbial
  • Drug Resistance, Multiple
  • Drug Therapy, Combination / therapeutic use*
  • Humans
  • Male
  • Mycetoma / drug therapy
  • Nocardia Infections / drug therapy*

Substances

  • Adjuvants, Immunologic
  • Anti-Bacterial Agents
  • Cephalosporins
  • Amikacin
  • Cefotaxime